{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:28:43Z","timestamp":1793921323081,"version":"4.8.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA258688"],"award-info":[{"award-number":["R01 CA258688"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","award":["93085"],"award-info":[{"award-number":["93085"]}],"id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA258688"],"award-info":[{"award-number":["R01 CA258688"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.xcrm.2025.102198","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T11:01:43Z","timestamp":1750417303000},"page":"102198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform"],"prefix":"10.1016","volume":"6","author":[{"given":"Yuqing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott J.","family":"Brea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin R.","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Rye","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Minwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Y.","family":"Tolstorukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"McGourty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lizotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Haratani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tran C.","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara M.","family":"Soroko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Kivlehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prafulla C.","family":"Gokhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cloud P.","family":"Paweletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Barbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2187-0801","authenticated-orcid":false,"given":"Thanh U.","family":"Barbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102198_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: Pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.xcrm.2025.102198_bib2","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102198_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102198_bib4","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102198_bib5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2025.102198_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102198_bib7","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102198_bib8","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102198_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41523-022-00386-1","article-title":"Immunotherapy for early triple negative breast cancer: research agenda for the next decade","volume":"8","author":"Tarantino","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.xcrm.2025.102198_bib10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.celrep.2015.12.029","article-title":"Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis","volume":"14","author":"Xia","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2025.102198_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2159-8290.CD-18-0689","article-title":"Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer","volume":"9","author":"Kitajima","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102198_bib12","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nri3921","article-title":"STING: infection, inflammation and cancer","volume":"15","author":"Barber","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102198_bib13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-22-2235","article-title":"Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced\/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102198_bib14","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study","volume":"34","author":"Nanda","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102198_bib15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2025.102198_bib16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","article-title":"Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study","volume":"167","author":"Dirix","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.xcrm.2025.102198_bib17","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrc1456","article-title":"High interstitial fluid pressure - an obstacle in cancer therapy","volume":"4","author":"Heldin","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.102198_bib18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/0008-5472.CAN-19-1310","article-title":"Phosphorylation of RAB7 by TBK1\/IKKepsilon Regulates Innate Immune Signaling in Triple-Negative Breast Cancer","volume":"80","author":"Ritter","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102198_bib19","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1016\/j.celrep.2017.11.061","article-title":"Trafficking-Mediated STING Degradation Requires Sorting to Acidified Endolysosomes and Can Be Targeted to Enhance Anti-tumor Response","volume":"21","author":"Gonugunta","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2025.102198_bib20","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1158\/2326-6066.CIR-22-0017","article-title":"Activation of Tumor-Cell STING Primes NK-Cell Therapy","volume":"10","author":"Knelson","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2025.102198_bib21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ijc.28021","article-title":"Comprehensive analysis of PTEN status in breast carcinomas","volume":"133","author":"Jones","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102198_bib22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature10933","article-title":"The clonal and mutational evolution spectrum of primary triple-negative breast cancers","volume":"486","author":"Shah","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102198_bib23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.clbc.2015.04.008","article-title":"Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications","volume":"15","author":"Millis","year":"2015","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.xcrm.2025.102198_bib24","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41586-023-06464-z","article-title":"Non-cell-autonomous cancer progression from chromosomal instability","volume":"620","author":"Li","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102198_bib25","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41586-022-04847-2","article-title":"cGAS-STING drives the IL-6-dependent survival of chromosomally instable cancers","volume":"607","author":"Hong","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102198_bib26","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1158\/2159-8290.CD-17-0833","article-title":"Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids","volume":"8","author":"Jenkins","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102198_bib27","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41401-018-0166-8","article-title":"CID1067700, a late endosome GTPase Rab7 receptor antagonist, attenuates brain atrophy, improves neurologic deficits and inhibits reactive astrogliosis in rat ischemic stroke","volume":"40","author":"Qin","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.xcrm.2025.102198_bib28","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.4049\/jimmunol.1601427","article-title":"Small Molecule Inhibition of Rab7 Impairs B Cell Class Switching and Plasma Cell Survival To Dampen the Autoantibody Response in Murine Lupus","volume":"197","author":"Lam","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102198_bib29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0168-3659(99)00027-9","article-title":"Poly(ethylene glycol)-containing hydrogels in drug delivery","volume":"62","author":"Peppas","year":"1999","journal-title":"J. Control. Release"},{"key":"10.1016\/j.xcrm.2025.102198_bib30","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.3390\/polym3041972","article-title":"Water Soluble Polymers for Pharmaceutical Applications","volume":"3","author":"Kadajji","year":"2011","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.xcrm.2025.102198_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2016.71","article-title":"Designing hydrogels for controlled drug delivery","volume":"1","author":"Li","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.xcrm.2025.102198_bib32","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.xcrm.2025.102198_bib33","first-page":"1399","article-title":"Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor","volume":"52","author":"Aslakson","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102198_bib34","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41563-022-01251-z","article-title":"STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity","volume":"21","author":"Dane","year":"2022","journal-title":"Nat. Mater."},{"key":"10.1016\/j.xcrm.2025.102198_bib35","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102198_bib36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41467-017-00573-w","article-title":"Signalling strength determines proapoptotic functions of STING","volume":"8","author":"Gulen","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102198_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade2526","article-title":"Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma","volume":"9","author":"Uslu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2025.102198_bib38","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2025.102198_bib39","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200844","article-title":"STING agonist promotes CAR T cell trafficking and persistence in breast cancer","volume":"218","author":"Xu","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2025.102198_bib40","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10549-012-2018-4","article-title":"Mesothelin, a novel immunotherapy target for triple negative breast cancer","volume":"133","author":"Tchou","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.xcrm.2025.102198_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114900","article-title":"Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival","volume":"9","author":"Tozbikian","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2025.102198_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn8264","article-title":"Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors","volume":"8","author":"Grosskopf","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2025.102198_bib43","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1172\/JCI87624","article-title":"Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors","volume":"127","author":"Smith","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102198_bib44","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nbt.3104","article-title":"Biopolymer implants enhance the efficacy of adoptive T-cell therapy","volume":"33","author":"Stephan","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2025.102198_bib45","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.3389\/fimmu.2020.02090","article-title":"Tumor-Derived cGAMP Regulates Activation of the Vasculature","volume":"11","author":"Campisi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102198_bib46","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1172\/JCI125413","article-title":"STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade","volume":"129","author":"Yang","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102198_bib47","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102198_bib48","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160149","article-title":"A prospective comparative study to evaluate the displacement of four commercially available breast biopsy markers","volume":"89","author":"Pinkney","year":"2016","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.xcrm.2025.102198_bib49","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s12282-018-0854-8","article-title":"Evaluation of the dislocation and long-term sonographic detectability of a hydrogel-based breast biopsy site marker","volume":"25","author":"Sakamoto","year":"2018","journal-title":"Breast Cancer"},{"key":"10.1016\/j.xcrm.2025.102198_bib50","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/modpathol.2017.96","article-title":"Hygroscopic sonographically detectable clips form characteristic breast and lymph node pseudocysts","volume":"31","author":"Carmon","year":"2018","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.xcrm.2025.102198_bib51","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/01.pas.0000161324.59219.ca","article-title":"The pathology of breast biopsy site marking devices","volume":"29","author":"Guarda","year":"2005","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.xcrm.2025.102198_bib52","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1038\/s41467-022-30568-1","article-title":"STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102198_bib53","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2214278119","article-title":"Tumor-targeted delivery of a STING agonist improvescancer immunotherapy","volume":"119","author":"Wu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102198_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099988","article-title":"DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization","volume":"9","author":"Downey","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2025.102198_bib55","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature07317","article-title":"STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling","volume":"455","author":"Ishikawa","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102198_bib56","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2025.102198_bib57","doi-asserted-by":"crossref","first-page":"15408","DOI":"10.1073\/pnas.1512832112","article-title":"STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity","volume":"112","author":"Demaria","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102198_bib58","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1312625","article-title":"Activated STING in a vascular and pulmonary syndrome","volume":"371","author":"Liu","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102198_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187532","article-title":"STING expression and response to treatment with STING ligands in premalignant and malignant disease","volume":"12","author":"Baird","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2025.102198_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14049","article-title":"Massively parallel digital transcriptional profiling of single cells","volume":"8","author":"Zheng","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102198_bib61","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2025.102198_bib62","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","article-title":"Scrublet: Computational Identification of Cell Doublets in Single-Cell Transcriptomic Data","volume":"8","author":"Wolock","year":"2019","journal-title":"Cell Syst."},{"key":"10.1016\/j.xcrm.2025.102198_bib63","article-title":"clusterProfiler 4.0: A universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation"},{"key":"10.1016\/j.xcrm.2025.102198_bib64","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1158\/2159-8290.CD-20-0913","article-title":"Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity","volume":"11","author":"Mahadevan","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102198_bib65","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","article-title":"Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor","volume":"32","author":"Kochenderfer","year":"2009","journal-title":"J. Immunother."},{"key":"10.1016\/j.xcrm.2025.102198_bib66","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41419-019-1711-1","article-title":"Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor","volume":"10","author":"Zhang","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xcrm.2025.102198_bib67","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-4939-6548-9_9","article-title":"Gammaretroviral Production and T Cell Transduction to Genetically Retarget Primary T Cells Against Cancer","volume":"1514","author":"Li","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.xcrm.2025.102198_bib68","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma","volume":"1","author":"Fernandez de Larrea","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102198_bib69","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1039\/C8LC00322J","article-title":"3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade","volume":"18","author":"Aref","year":"2018","journal-title":"Lab Chip"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266637912500271X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266637912500271X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T21:43:34Z","timestamp":1762638214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266637912500271X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S266637912500271X"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102198","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102198","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102198"}}